Genomic studies in fragile X premutation carriers

Reymundo Lozano, Randi J Hagerman, Michael Duyzend, Dejan B. Budimirovic, Evan E. Eichler, Flora Tassone

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The FMR1 premutation is defined as having 55 to 200 CGG repeats in the 5′ untranslated region of the fragile X mental retardation 1 gene (FMR1). The clinical involvement has been well characterized for fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI). The behavior/psychiatric and other neurological manifestations remain to be specified as well as the molecular mechanisms that will explain the phenotypic variability observed in individuals with the FMR1 premutation. Methods: Here we describe a small pilot study of copy number variants (CNVs) in 56 participants with a premutation ranging from 55 to 192 repeats. The participants were divided into four different clinical groups for the analysis: those with behavioral problems but no autism spectrum disorder (ASD); those with ASD but without neurological problems; those with ASD and neurological problems including seizures; and those with neurological problems without ASD. Results: We found 12 rare CNVs (eight duplications and four deletions) in 11 cases (19.6%) that were not found in approximately 8,000 controls. Three of them were at 10q26 and two at Xp22.3, with small areas of overlap. The CNVs were more commonly identified in individuals with neurological involvement and ASD. Conclusions: The frequencies were not statistically significant across the groups. There were no significant differences in the psychometric and behavior scores among all groups. Further studies are necessary to determine the frequency of second genetic hits in individuals with the FMR1 premutation; however, these preliminary results suggest that genomic studies can be useful in understanding the molecular etiology of clinical involvement in premutation carriers with ASD and neurological involvement.

Original languageEnglish (US)
Article number27
JournalJournal of Neurodevelopmental Disorders
Volume6
Issue number1
DOIs
StatePublished - Jul 30 2014

Fingerprint

Intellectual Disability
Genes
Primary Ovarian Insufficiency
5' Untranslated Regions
Neurologic Manifestations
Psychometrics
Psychiatry
Autism Spectrum Disorder
Seizures

Keywords

  • ASD
  • Autism
  • FMR1 gene
  • Neurodevelopmental disorders
  • Neurological disorders
  • Premutation
  • Second hit

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cognitive Neuroscience
  • Pediatrics, Perinatology, and Child Health

Cite this

Genomic studies in fragile X premutation carriers. / Lozano, Reymundo; Hagerman, Randi J; Duyzend, Michael; Budimirovic, Dejan B.; Eichler, Evan E.; Tassone, Flora.

In: Journal of Neurodevelopmental Disorders, Vol. 6, No. 1, 27, 30.07.2014.

Research output: Contribution to journalArticle

Lozano, Reymundo ; Hagerman, Randi J ; Duyzend, Michael ; Budimirovic, Dejan B. ; Eichler, Evan E. ; Tassone, Flora. / Genomic studies in fragile X premutation carriers. In: Journal of Neurodevelopmental Disorders. 2014 ; Vol. 6, No. 1.
@article{27584ecce2904ca2b59dfad55db93040,
title = "Genomic studies in fragile X premutation carriers",
abstract = "Background: The FMR1 premutation is defined as having 55 to 200 CGG repeats in the 5′ untranslated region of the fragile X mental retardation 1 gene (FMR1). The clinical involvement has been well characterized for fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI). The behavior/psychiatric and other neurological manifestations remain to be specified as well as the molecular mechanisms that will explain the phenotypic variability observed in individuals with the FMR1 premutation. Methods: Here we describe a small pilot study of copy number variants (CNVs) in 56 participants with a premutation ranging from 55 to 192 repeats. The participants were divided into four different clinical groups for the analysis: those with behavioral problems but no autism spectrum disorder (ASD); those with ASD but without neurological problems; those with ASD and neurological problems including seizures; and those with neurological problems without ASD. Results: We found 12 rare CNVs (eight duplications and four deletions) in 11 cases (19.6{\%}) that were not found in approximately 8,000 controls. Three of them were at 10q26 and two at Xp22.3, with small areas of overlap. The CNVs were more commonly identified in individuals with neurological involvement and ASD. Conclusions: The frequencies were not statistically significant across the groups. There were no significant differences in the psychometric and behavior scores among all groups. Further studies are necessary to determine the frequency of second genetic hits in individuals with the FMR1 premutation; however, these preliminary results suggest that genomic studies can be useful in understanding the molecular etiology of clinical involvement in premutation carriers with ASD and neurological involvement.",
keywords = "ASD, Autism, FMR1 gene, Neurodevelopmental disorders, Neurological disorders, Premutation, Second hit",
author = "Reymundo Lozano and Hagerman, {Randi J} and Michael Duyzend and Budimirovic, {Dejan B.} and Eichler, {Evan E.} and Flora Tassone",
year = "2014",
month = "7",
day = "30",
doi = "10.1186/1866-1955-6-27",
language = "English (US)",
volume = "6",
journal = "Journal of Neurodevelopmental Disorders",
issn = "1866-1947",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Genomic studies in fragile X premutation carriers

AU - Lozano, Reymundo

AU - Hagerman, Randi J

AU - Duyzend, Michael

AU - Budimirovic, Dejan B.

AU - Eichler, Evan E.

AU - Tassone, Flora

PY - 2014/7/30

Y1 - 2014/7/30

N2 - Background: The FMR1 premutation is defined as having 55 to 200 CGG repeats in the 5′ untranslated region of the fragile X mental retardation 1 gene (FMR1). The clinical involvement has been well characterized for fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI). The behavior/psychiatric and other neurological manifestations remain to be specified as well as the molecular mechanisms that will explain the phenotypic variability observed in individuals with the FMR1 premutation. Methods: Here we describe a small pilot study of copy number variants (CNVs) in 56 participants with a premutation ranging from 55 to 192 repeats. The participants were divided into four different clinical groups for the analysis: those with behavioral problems but no autism spectrum disorder (ASD); those with ASD but without neurological problems; those with ASD and neurological problems including seizures; and those with neurological problems without ASD. Results: We found 12 rare CNVs (eight duplications and four deletions) in 11 cases (19.6%) that were not found in approximately 8,000 controls. Three of them were at 10q26 and two at Xp22.3, with small areas of overlap. The CNVs were more commonly identified in individuals with neurological involvement and ASD. Conclusions: The frequencies were not statistically significant across the groups. There were no significant differences in the psychometric and behavior scores among all groups. Further studies are necessary to determine the frequency of second genetic hits in individuals with the FMR1 premutation; however, these preliminary results suggest that genomic studies can be useful in understanding the molecular etiology of clinical involvement in premutation carriers with ASD and neurological involvement.

AB - Background: The FMR1 premutation is defined as having 55 to 200 CGG repeats in the 5′ untranslated region of the fragile X mental retardation 1 gene (FMR1). The clinical involvement has been well characterized for fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI). The behavior/psychiatric and other neurological manifestations remain to be specified as well as the molecular mechanisms that will explain the phenotypic variability observed in individuals with the FMR1 premutation. Methods: Here we describe a small pilot study of copy number variants (CNVs) in 56 participants with a premutation ranging from 55 to 192 repeats. The participants were divided into four different clinical groups for the analysis: those with behavioral problems but no autism spectrum disorder (ASD); those with ASD but without neurological problems; those with ASD and neurological problems including seizures; and those with neurological problems without ASD. Results: We found 12 rare CNVs (eight duplications and four deletions) in 11 cases (19.6%) that were not found in approximately 8,000 controls. Three of them were at 10q26 and two at Xp22.3, with small areas of overlap. The CNVs were more commonly identified in individuals with neurological involvement and ASD. Conclusions: The frequencies were not statistically significant across the groups. There were no significant differences in the psychometric and behavior scores among all groups. Further studies are necessary to determine the frequency of second genetic hits in individuals with the FMR1 premutation; however, these preliminary results suggest that genomic studies can be useful in understanding the molecular etiology of clinical involvement in premutation carriers with ASD and neurological involvement.

KW - ASD

KW - Autism

KW - FMR1 gene

KW - Neurodevelopmental disorders

KW - Neurological disorders

KW - Premutation

KW - Second hit

UR - http://www.scopus.com/inward/record.url?scp=84960129345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960129345&partnerID=8YFLogxK

U2 - 10.1186/1866-1955-6-27

DO - 10.1186/1866-1955-6-27

M3 - Article

AN - SCOPUS:84960129345

VL - 6

JO - Journal of Neurodevelopmental Disorders

JF - Journal of Neurodevelopmental Disorders

SN - 1866-1947

IS - 1

M1 - 27

ER -